189 related articles for article (PubMed ID: 10091030)
1. In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia.
Isenberg HD; Alperstein P; France K
Diagn Microbiol Infect Dis; 1999 Feb; 33(2):81-6. PubMed ID: 10091030
[TBL] [Abstract][Full Text] [Related]
2. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.
Visalli MA; Bajaksouzian S; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1997 Jul; 41(7):1475-81. PubMed ID: 9210669
[TBL] [Abstract][Full Text] [Related]
3. Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia.
Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 Aug; 42(8):2002-5. PubMed ID: 9687397
[TBL] [Abstract][Full Text] [Related]
4. Pseudomonas aeruginosa in vitro corneal isolate sensitivity to ofloxacin, ciprofloxacin, and trovafloxacin: a comparative study.
Song A; McCulley TJ; Lam BL; Feuer WJ; Miller D; Alfonso EC
Am J Ophthalmol; 2001 Jun; 131(6):795-6. PubMed ID: 11384579
[TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
[TBL] [Abstract][Full Text] [Related]
7. Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia.
Zhang L; Li XZ; Poole K
J Antimicrob Chemother; 2001 Oct; 48(4):549-52. PubMed ID: 11581236
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
Cunha BA; Qadri SM; Ueno Y; Walters EA; Domenico P
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
[TBL] [Abstract][Full Text] [Related]
9. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
Seifert H
Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli.
Fass RJ; Barnishan J; Solomon MC; Ayers LW
Antimicrob Agents Chemother; 1996 Jun; 40(6):1412-8. PubMed ID: 8726011
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin.
Isenberg HD; Alperstein P; France K
Diagn Microbiol Infect Dis; 1998 Oct; 32(2):115-8. PubMed ID: 9823535
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.
Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):814-9. PubMed ID: 11783700
[TBL] [Abstract][Full Text] [Related]
13. The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
Erdem I; Kaynar-Tascioglu J; Kaya B; Goktas P
Int J Antimicrob Agents; 2002 Nov; 20(5):384-6. PubMed ID: 12431875
[TBL] [Abstract][Full Text] [Related]
14. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest.
Dembry LM; Farrel PA; Orcutt DR; Gerrity LA; Andriole VT
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():35-42. PubMed ID: 9222068
[TBL] [Abstract][Full Text] [Related]
15. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
Burgess DS; Hastings RW
Diagn Microbiol Infect Dis; 2000 Sep; 38(1):37-41. PubMed ID: 11025182
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial interactions of trovafloxacin and extended-spectrum cephalosporins or azithromycin tested against clinical isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Johnson DM; Jones RN; Pfaller MA
J Antimicrob Chemother; 1998 Oct; 42(4):557-9. PubMed ID: 9818765
[No Abstract] [Full Text] [Related]
17. Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa.
McNabb J; Quintiliani R; Nightingale CH; Nicolau DP
Chemotherapy; 2000; 46(6):383-9. PubMed ID: 11053903
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis.
Bonacorsi S; Fitoussi F; Lhopital S; Bingen E
Antimicrob Agents Chemother; 1999 Feb; 43(2):213-7. PubMed ID: 9925508
[TBL] [Abstract][Full Text] [Related]
19. In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa.
Pendland SL; Messick CR; Jung R
Diagn Microbiol Infect Dis; 2002 Jan; 42(1):75-8. PubMed ID: 11821176
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of trovafloxacin against ciprofloxacin-susceptible and -resistant clinical bacterial isolates and assessment of the trovafloxacin disk test.
Fuchs PC; Barry AL; Brown SD
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):33-8. PubMed ID: 9990473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
